Sensus Healthcare price target lowered to $4 from $7 at Alliance Global

Alliance Global Partners analyst Ben Haynor lowered the firm’s price target on Sensus Healthcare to $4 from $7 and keeps a Buy rating on the shares. Despite the company’s below-expectations Q3, management seems to have high confidence of achieving their target of 60-plus systems shipped during 2023, the analyst tells investors in a research note. The firm believes Sensus will need additional cash and thinks a more conservative stance is warranted given the recent volatility in both the company’s results and the market. However, it thinks the stock offers a “highly favorable risk-reward for investors willing to tolerate volatility.”